Dr. Peter Riedell, MD
Claim this profileUniversity of Chicago
Expert in Lymphoma
Studies B-Cell Lymphoma
15 reported clinical trials
26 drugs studied
Area of expertise
1Lymphoma
Global LeaderCD19 positive
CCND1 positive
t(11;14) positive
2B-Cell Lymphoma
CD19 positive
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Peter Riedell, MD is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting1 award Phase 1 & 2
More about Peter Riedell, MD
Clinical Trial Related3 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Peter Riedell, MD has experience with
- Ibrutinib
- CLBR001
- Duvelisib
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- SWI019
Breakdown of trials Peter Riedell, MD has run
Lymphoma
B-Cell Lymphoma
Mantle Cell Lymphoma
Chronic B-Cell Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter Riedell, MD specialize in?
Peter Riedell, MD focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are CCND1 positive.
Is Peter Riedell, MD currently recruiting for clinical trials?
Yes, Peter Riedell, MD is currently recruiting for 8 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Peter Riedell, MD has studied deeply?
Yes, Peter Riedell, MD has studied treatments such as Ibrutinib, CLBR001, Duvelisib.
What is the best way to schedule an appointment with Peter Riedell, MD?
Apply for one of the trials that Peter Riedell, MD is conducting.
What is the office address of Peter Riedell, MD?
The office of Peter Riedell, MD is located at: University of Chicago, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.